Jupiter Topco LLC Takes $24.91 Million Position in PROCEPT BioRobotics Corporation $PRCT

Jupiter Topco LLC acquired a new stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,103,404 shares of the company’s stock, valued at approximately $24,914,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Advisory Services Network LLC raised its stake in PROCEPT BioRobotics by 1.3% in the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after purchasing an additional 250 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in PROCEPT BioRobotics by 20.3% in the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after purchasing an additional 337 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of PROCEPT BioRobotics by 4.7% during the 4th quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock worth $306,000 after purchasing an additional 438 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of PROCEPT BioRobotics by 1.4% during the 2nd quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock worth $2,848,000 after purchasing an additional 693 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PRCT shares. Jefferies Financial Group reissued a “hold” rating and set a $20.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. TD Cowen cut their price target on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Leerink Partners cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. UBS Group lowered PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price for the company. in a research note on Tuesday, July 28th. Finally, Robert W. Baird set a $20.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.00.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms, including Kaplan Fox, Rosen Law Firm and Hagens Berman, announced or reiterated that a securities class action has been filed on behalf of investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors seeking to serve as lead plaintiff must act by September 22, 2026. Kaplan Fox class-action notice
• Negative Sentiment: The complaint reportedly alleges that PROCEPT understated weakness in unit handpiece sales and failed to disclose elevated customer inventory, while using repeated late-quarter bulk discounts to pull demand forward. The allegations concern potential violations of federal securities laws and could increase litigation costs, reputational risk and investor uncertainty; they have not been proven in court. Hagens Berman PROCEPT investor alert
• Negative Sentiment: The unusually high number of law-firm solicitations over the past two days keeps attention focused on the lawsuit and the company’s prior sales and inventory disclosures. Although the notices do not introduce a new financial result or regulatory action, continued headlines may weigh on sentiment and limit the stock’s recovery.

PROCEPT BioRobotics Trading Up 1.1%

PRCT stock opened at $20.83 on Friday. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -10.74 and a beta of 0.89. The business has a fifty day simple moving average of $20.32 and a 200-day simple moving average of $23.93. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The firm had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) earnings per share. On average, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Larry L. Wood purchased 23,900 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the acquisition, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 1,000 shares of company stock valued at $28,480 over the last three months. 4.00% of the stock is owned by company insiders.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.